FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-0287									
П		la considerate									

l	OMB Number:	3235-02	28
	Estimated average burde	en	
ı	hours per response.		n

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* FAHIM RAAFAT E F						2. Issuer Name and Ticker or Trading Symbol NABI BIOPHARMACEUTICALS [ NABI ]									ck all applic	nship of Reporting I applicable) Director Officer (give title		son(s) to Issu 10% Ow Other (s	vner	
(Last) (First) (Middle) C/O NABI BIOPHARMACEUTICALS 5800 PARK OF COMMERCE BLVD., N.W.						3. Date of Earliest Transaction (Month/Day/Year) 02/24/2006									below)		ch. &	below)	, , , , , , , , , , , , , , , , , , , ,	
(Street) BOCA RATON FL					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	5. Individual or Joint/Group Filing (Check Applicable .ine)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					<u> </u>	tive Securities Acquired, Disposed of, or Benefic														
		Tab	ole I - Nor	n-Deriv	vative	e Se	curities	s Acc	quired, [	Disp	osed o	f, or Be	enefic	ially	Owned					
1. Title of Security (Instr. 3)  2. Transa Date (Month/Date)						Execution Date,		3. Transaction Code (Instr. bisposed 5)					and Securitie Beneficia		es For ally (D) Following (I) (		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)		ce	Transaction(s) (Instr. 3 and 4)					
Common Stock 02/24/					4/200	2006		A		37,859	37,859 <sup>(1)</sup> A		\$ <mark>0</mark>	50,312.4267			D			
		7	Table II -						ired, Di options						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable an Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisable		xpiration late	Title	Amor or Numl of Share	ber						
Stock Option (right to buy)	\$3.83	02/24/2006			A		54,345		03/01/2009	0	2/24/2016	Common Stock	54,3	45	\$0	54,345	5	D		

## **Explanation of Responses:**

1. Restricted stock that vests on March 1, 2009.

## Remarks:

/s/ James E. Dawson, as attorney-in-fact

02/28/2006

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.